Sanofi (NASDAQ:SNY) Now Covered by Analysts at BNP Paribas

Research analysts at BNP Paribas started coverage on shares of Sanofi (NASDAQ:SNY - Get Free Report) in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage set an "outperform" rating and a $65.00 price target on the stock. BNP Paribas' target price would suggest a potential upside of 27.70% from the company's previous close.

Several other analysts have also recently commented on SNY. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.34 on Tuesday, reaching $50.90. The company's stock had a trading volume of 2,856,361 shares, compared to its average volume of 2,354,311. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 52-week low of $45.79 and a 52-week high of $60.12. The stock's 50-day moving average is $54.73 and its two-hundred day moving average is $52.19. The stock has a market capitalization of $128.59 billion, a P/E ratio of 20.44, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of large investors have recently modified their holdings of SNY. Invesco Ltd. increased its holdings in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after buying an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares in the last quarter. Boston Partners raised its holdings in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after acquiring an additional 369,530 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.